Efficacy and Safety of Roxadustat in Patients with Chronic Kidney Disease: An Updated Meta-Analysis of Randomized Controlled Trials including 6,518 Patients

Table 5

TEAEs occurring in the treatment groups in NDD study.

Parameter	value for heterogeneity (, )	RR (95% CI)	value
TEAEs	,	1.02 (0.95, 1.09)
Serious TEAEs	,	1.09 (0.94, 1.25)
ESKD	,	1.38 (0.85, 2.25)
Upper respiratory tract infection	,	0.79 (0.58, 1.08)
Urinary tract infection	,	0.46 (0.05, 4.55)
Cough	,	0.61 (0.13, 2.98)
Pneumonia	,	1.14 (0.76, 1.71)
Viral upper respiratory tract infection	,	1.50 (0.87, 2.61)
Nasopharyngitis	,	1.27 (0.59, 2.75)
Hypertension	,	1.45 (1.12, 1.87)
Hyperkalemia	,	1.41 (1.08, 1.85)
Metabolic acidosis	,	1.77 (0.24, 13.04)
Insomnia	,	3.17 (1.66, 6.07)
Gout	,	0.72 (0.43, 1.20)
Back pain	,	0.47 (0.03, 8.90)
Headache	,	1.16 (0.82, 1.66)
Vomiting	,	1.38 (0.85, 2.24)
Nausea	,	1.79 (1.26, 2.55)
Dizziness	,	0.77 (0.53, 1.11)
Muscle spasms	,	1.04 (0.20, 5.44)
Anemia	,	0.18 (0.11, 0.31)
Diarrhea	,	1.38 (1.00, 1.92)
Peripheral edema	,	1.38 (1.02, 1.87)
Fever	,	1.02 (0.17, 6.12)
Pruritus	,	2.28 (0.65, 7.93)
Asthenia	,	1.48 (0.77, 2.85)
Gastrointestinal hemorrhage	,	0.82 (0.25, 2.75)

TEAEs: treatment emerged adverse event.